Weisheng Zhuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weisheng Zhuang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Di Zhang
School of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China
10 shared publicationsHeling Wang
School of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China
9 shared publicationsQiaohua Han
School of Clinical Medicine, Henan University, Zhengzhou, China
9 shared publicationsShenhong Ma
School of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China
9 shared publicationsXu Wang
School of Rehabilitation Medicine, Henan University of Chinese Medicine, Zhengzhou, China
9 shared publicationsBeibei Lei
Rehabilitation Medicine College, Henan University of Chinese Medicine
8 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1965765
Comparative effectiveness of telerehabilitation vs. face-to-face rehabilitation in adults with chronic low back pain: a systematic review and meta-analysis of randomized controlled trials
Background: Chronic low back pain (CLBP) is a major cause of disability worldwide and creates substantial rehabilitation demand. When core rehabilitation content is similar, the comparative effectiveness of telerehabilitation (TR) and face-to-face rehabilitation as delivery modes remains unclear. Methods: Methods: This meta-analysis used strict eligibility criteria to distinguish the two delivery pathways and better isolate delivery-mode effects. PubMed, Web of Science, the Cochrane Library, and Embase were searched for randomized controlled trials in adults with CLBP. Paper-based home exercise programs, continuous hybrid delivery, and remote-assessment-only designs were excluded. Random-effects meta-analyses used standardized mean differences (SMDs) with 95% confidence intervals (CIs). RoB 2 and GRADE assessed risk of bias and evidence certainty. Sensitivity and subgroup analyses were conducted. Results: Ten trials involving 562 participants were included. Content-matched primary analyses found no significant difference between TR and face-to-face rehabilitation in pain intensity (7 trials; SMD = −0.05, 95% CI − 0.34 to 0.24; very low certainty) or functional disability (8 trials; SMD = 0.22, 95% CI − 0.07 to 0.52; low certainty). In secondary analyses including two trials that provided manual therapy only to the face-to-face group, pain intensity did not differ significantly (9 trials; SMD = −0.01, 95% CI − 0.26 to 0.24), whereas functional disability favored face-to-face rehabilitation (10 trials; SMD = 0.26, 95% CI 0.01 to 0.52). Subgroup interaction tests were nonsignificant for intervention duration, weekly treatment frequency, and supervision status. Conclusion: When rehabilitation content was similar, TR and face-to-face rehabilitation showed no statistically significant differences in pain intensity or functional disability. However, these findings should not be interpreted as evidence of equivalent effectiveness between TR and face-to-face rehabilitation, because the certainty of evidence was low for functional disability and very low for pain intensity, and the functional disability estimate was sensitive to the exclusion of one study. Future high-quality trials with comparable interventions and longer follow-up are needed, particularly direct comparisons of supervised and unsupervised TR. Systematic review registration: PROSPERO, CRD420261467122.
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1965765
Open AccessComparative effectiveness of telerehabilitation vs. face-to-face rehabilitation in adults with chronic low back pain: a systematic review and meta-analysis of randomized controlled trials
Background: Chronic low back pain (CLBP) is a major cause of disability worldwide and creates substantial rehabilitation demand. When core rehabilitation content is similar, the comparative effectiveness of telerehabilitation (TR) and face-to-face rehabilitation as delivery modes remains unclear. Methods: Methods: This meta-analysis used strict eligibility criteria to distinguish the two delivery pathways and better isolate delivery-mode effects. PubMed, Web of Science, the Cochrane Library, and Embase were searched for randomized controlled trials in adults with CLBP. Paper-based home exercise programs, continuous hybrid delivery, and remote-assessment-only designs were excluded. Random-effects meta-analyses used standardized mean differences (SMDs) with 95% confidence intervals (CIs). RoB 2 and GRADE assessed risk of bias and evidence certainty. Sensitivity and subgroup analyses were conducted. Results: Ten trials involving 562 participants were included. Content-matched primary analyses found no significant difference between TR and face-to-face rehabilitation in pain intensity (7 trials; SMD = −0.05, 95% CI − 0.34 to 0.24; very low certainty) or functional disability (8 trials; SMD = 0.22, 95% CI − 0.07 to 0.52; low certainty). In secondary analyses including two trials that provided manual therapy only to the face-to-face group, pain intensity did not differ significantly (9 trials; SMD = −0.01, 95% CI − 0.26 to 0.24), whereas functional disability favored face-to-face rehabilitation (10 trials; SMD = 0.26, 95% CI 0.01 to 0.52). Subgroup interaction tests were nonsignificant for intervention duration, weekly treatment frequency, and supervision status. Conclusion: When rehabilitation content was similar, TR and face-to-face rehabilitation showed no statistically significant differences in pain intensity or functional disability. However, these findings should not be interpreted as evidence of equivalent effectiveness between TR and face-to-face rehabilitation, because the certainty of evidence was low for functional disability and very low for pain intensity, and the functional disability estimate was sensitive to the exclusion of one study. Future high-quality trials with comparable interventions and longer follow-up are needed, particularly direct comparisons of supervised and unsupervised TR. Systematic review registration: PROSPERO, CRD420261467122.
- 3 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 606
Efficacy of repetitive transcranial magnetic stimulation for post-stroke spasticity: a meta-analysis of randomized controlled trials
Objective This study aimed to investigate the efficacy of repetitive transcranial magnetic stimulation (rTMS) for improving spasticity, motor function, and activities of daily living (ADL) in patients with post-stroke spasticity (PSS), and to perform a comprehensive analysis of key factors related to its therapeutic effect. Methods Relevant randomized controlled trials (RCTs) were retrieved from four databases. Meta-analysis was conducted using RevMan, and the quality of evidence was assessed with the GRADEpro tool. Results Overall, 13 studies (encompassing 18 RCTs) were included. The results demonstrated that rTMS alleviated PSS (MD = − 0.23, 95% CI: −0.43 to − 0.02, P = 0.03) and improved motor (MD = 2.46, 95% CI: 1.54 to 3.38, P < 0.00001), whereas it showed no significant effect on ADL (SMD = 0.31, 95% CI: -0.06 to 0.67, P = 0.10). For spasticity, stimulating the unaffected hemisphere achieved significantly better efficacy (SMD = -0.19, 95% CI: -0.37 to -0.00, P = 0.05), and combined high and low frequency rTMS showed promising effects (SMD = -0.65, 95% CI: -0.94 to -0.36, P < 0.00001). For motor function, rTMS yielded greater improvement in upper limb PSS patients (SMD = 3.58, 95% CI: 2.18 to 4.98, P < 0.00001). Within a certain range, pulse number was positively correlated with motor improvement (β = 2.46, 95% CI: 0.097 to 4.81, P = 0.043). Conclusion Moderate to high quality evidence demonstrates that rTMS can potentially alleviate PSS and improve motor function in patients, whereas its efficacy in improving ADL remains unclear, with very low quality of evidence. In addition, stimulation frequency, stimulation site, pulse number, and affected site are key moderators of rTMS efficacy. These findings guide the clinical optimization of rTMS regimens, and future research is required to identify specific parameter thresholds.
- 3 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 606
Efficacy of repetitive transcranial magnetic stimulation for post-stroke spasticity: a meta-analysis of randomized controlled trials
Objective This study aimed to investigate the efficacy of repetitive transcranial magnetic stimulation (rTMS) for improving spasticity, motor function, and activities of daily living (ADL) in patients with post-stroke spasticity (PSS), and to perform a comprehensive analysis of key factors related to its therapeutic effect. Methods Relevant randomized controlled trials (RCTs) were retrieved from four databases. Meta-analysis was conducted using RevMan, and the quality of evidence was assessed with the GRADEpro tool. Results Overall, 13 studies (encompassing 18 RCTs) were included. The results demonstrated that rTMS alleviated PSS (MD = − 0.23, 95% CI: −0.43 to − 0.02, P = 0.03) and improved motor (MD = 2.46, 95% CI: 1.54 to 3.38, P < 0.00001), whereas it showed no significant effect on ADL (SMD = 0.31, 95% CI: -0.06 to 0.67, P = 0.10). For spasticity, stimulating the unaffected hemisphere achieved significantly better efficacy (SMD = -0.19, 95% CI: -0.37 to -0.00, P = 0.05), and combined high and low frequency rTMS showed promising effects (SMD = -0.65, 95% CI: -0.94 to -0.36, P < 0.00001). For motor function, rTMS yielded greater improvement in upper limb PSS patients (SMD = 3.58, 95% CI: 2.18 to 4.98, P < 0.00001). Within a certain range, pulse number was positively correlated with motor improvement (β = 2.46, 95% CI: 0.097 to 4.81, P = 0.043). Conclusion Moderate to high quality evidence demonstrates that rTMS can potentially alleviate PSS and improve motor function in patients, whereas its efficacy in improving ADL remains unclear, with very low quality of evidence. In addition, stimulation frequency, stimulation site, pulse number, and affected site are key moderators of rTMS efficacy. These findings guide the clinical optimization of rTMS regimens, and future research is required to identify specific parameter thresholds.
- Open Access
- 28 May 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
Efficacy and safety of biological agents and physical therapies for delayed union or nonunion of fractures: a network meta-analysis of randomized controlled trials
Background: Delayed and nonunion fractures remain a significant clinical challenge in orthopedics. This study compared the effects of biologics and physical therapies for delayed or nonunion fractures. Methods: We comprehensively searched and included randomized controlled trials (RCTs) investigating biologics and physical therapies for delayed or nonunion fractures; the outcomes included healing rate, healing time and adverse events. We ranked the interventions’ therapeutic efficacy through data analysis. Results: Twenty-seven RCTs (involving 1495 patients and 15 interventions) were included. For fracture healing rate, bone marrow aspirate (BMA) combined with autologous cancellous bone (ACB) exhibited significantly better efficacy than ACB alone (OR = 8.14, 95% CI: 1.69 to 39.32). SUCRA ranking revealed that BMA + ACB (96%), platelet-rich plasma (PRP) + ACB (77.3%) and bone morphogenetic protein (BMP) + ACB (70.5%) ranked among the top three interventions for fracture healing rate. For fracture healing time, LIPUS (SMD = -9.33, 95% CI: -12.94 to -5.73) and PRP + ACB (SMD = -2.43, 95% CI: -4.14 to -0.72) both significantly reduced the fracture healing time relative to ACB. For adverse events, BMA + ACB (OR = 0.12, 95% CI: 0.03 to 0.59) and BMP (OR = 0.15, 95% CI: 0.04 to 0.61) had the lowest risk of adverse events relative to ACB alone. Conclusion: Preliminary evidence suggests that among currently available biologics and physical therapies, BMA combined with ACB may be associated with a higher fracture healing rate. LIPUS may help shorten the healing time in patients with mild delayed and nonunion fractures, while BMA combined with ACB potentially exhibits the lowest risk of adverse events. However, the quality of current evidence is low, and these findings require further validation through large-scale RCTs.
- 28 May 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
Open AccessEfficacy and safety of biological agents and physical therapies for delayed union or nonunion of fractures: a network meta-analysis of randomized controlled trials
Background: Delayed and nonunion fractures remain a significant clinical challenge in orthopedics. This study compared the effects of biologics and physical therapies for delayed or nonunion fractures. Methods: We comprehensively searched and included randomized controlled trials (RCTs) investigating biologics and physical therapies for delayed or nonunion fractures; the outcomes included healing rate, healing time and adverse events. We ranked the interventions’ therapeutic efficacy through data analysis. Results: Twenty-seven RCTs (involving 1495 patients and 15 interventions) were included. For fracture healing rate, bone marrow aspirate (BMA) combined with autologous cancellous bone (ACB) exhibited significantly better efficacy than ACB alone (OR = 8.14, 95% CI: 1.69 to 39.32). SUCRA ranking revealed that BMA + ACB (96%), platelet-rich plasma (PRP) + ACB (77.3%) and bone morphogenetic protein (BMP) + ACB (70.5%) ranked among the top three interventions for fracture healing rate. For fracture healing time, LIPUS (SMD = -9.33, 95% CI: -12.94 to -5.73) and PRP + ACB (SMD = -2.43, 95% CI: -4.14 to -0.72) both significantly reduced the fracture healing time relative to ACB. For adverse events, BMA + ACB (OR = 0.12, 95% CI: 0.03 to 0.59) and BMP (OR = 0.15, 95% CI: 0.04 to 0.61) had the lowest risk of adverse events relative to ACB alone. Conclusion: Preliminary evidence suggests that among currently available biologics and physical therapies, BMA combined with ACB may be associated with a higher fracture healing rate. LIPUS may help shorten the healing time in patients with mild delayed and nonunion fractures, while BMA combined with ACB potentially exhibits the lowest risk of adverse events. However, the quality of current evidence is low, and these findings require further validation through large-scale RCTs.
- Open Access
- 23 May 2026
- Published by Scientific Scholar in Journal of Neurosciences in Rural Practice
- Vol. 17, 322-325
Severe closed-mouth oromandibular dystonia secondary to stroke
This case report describes a 68-year-old female patient with secondary closed-mouth oromandibular dystonia (OMD) following intracerebral hemorrhage, presenting with severe trismus that significantly impairs eating and speech. The patient underwent precise Botulinum Toxin Type A (BoNT-A) injection guided by ultrasound and electromyography. Systematic temporomandibular joint (TMJ) manual rehabilitation therapy commenced the following day and was administered 5 sessions per week for three weeks. Mouth opening degree and Modified Barthel Index (MBI) were assessed at baseline, 1 week post-treatment, 2 weeks post-treatment, 6 weeks post-treatment, and at the 2-month follow-up. Following treatment, the patient’s mouth opening degree increased from 0 mm to 36 mm, and the MBI score improved from 35 to 65. The patient resumed oral feeding, with significantly enhanced speech function. At the 2-month follow-up, therapeutic efficacy remained stable with no adverse reactions observed. Ultrasound- and electromyography-guided precise BoNT-A injection combined with TMJ manual rehabilitation represents an effective treatment strategy for this patient, significantly improving their mouth opening function and quality of life.
- 23 May 2026
- Published by Scientific Scholar in Journal of Neurosciences in Rural Practice
- Vol. 17, 322-325
Open AccessSevere closed-mouth oromandibular dystonia secondary to stroke
This case report describes a 68-year-old female patient with secondary closed-mouth oromandibular dystonia (OMD) following intracerebral hemorrhage, presenting with severe trismus that significantly impairs eating and speech. The patient underwent precise Botulinum Toxin Type A (BoNT-A) injection guided by ultrasound and electromyography. Systematic temporomandibular joint (TMJ) manual rehabilitation therapy commenced the following day and was administered 5 sessions per week for three weeks. Mouth opening degree and Modified Barthel Index (MBI) were assessed at baseline, 1 week post-treatment, 2 weeks post-treatment, 6 weeks post-treatment, and at the 2-month follow-up. Following treatment, the patient’s mouth opening degree increased from 0 mm to 36 mm, and the MBI score improved from 35 to 65. The patient resumed oral feeding, with significantly enhanced speech function. At the 2-month follow-up, therapeutic efficacy remained stable with no adverse reactions observed. Ultrasound- and electromyography-guided precise BoNT-A injection combined with TMJ manual rehabilitation represents an effective treatment strategy for this patient, significantly improving their mouth opening function and quality of life.
- Open Access
- 23 May 2026
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 23 (1)
Efficacy of vibration therapy on physical function, activity and participation in people with stroke: a systematic review and meta-analysis of randomized controlled trials
This study aimed to explore the effectiveness of vibration therapy (VT) in improving physical function, activity, and participation in people with stroke.
- 23 May 2026
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 23 (1)
Open AccessEfficacy of vibration therapy on physical function, activity and participation in people with stroke: a systematic review and meta-analysis of randomized controlled trials
This study aimed to explore the effectiveness of vibration therapy (VT) in improving physical function, activity, and participation in people with stroke.
- 9 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 128
Efficacy and safety of tACS in older adults with cognitive impairment: a systematic review and meta-analysis
Purpose To assess the safety and effectiveness of tACS as a therapeutic intervention for older adults with cognitive impairment. Materials and methods From the time of library construction until March 3, 2025, we conducted a comprehensive search of the databases PubMed, Embase, Web of Science and Cochrane Library. Additionally, we manually examined the references in the articles. The outcome indicators were cognitive function, which included memory function, attention, overall cognition, as well as safety. Results 6 publications with a total of 888 subjects were included. The tACS group did better at treating cognitive impairment, especially memory problems (SMD = 0.7, 95% Cl = 0.29 to 1.12, I2 = 52%, P = 0.0009) and overall cognition (SMD = 1.97, 95% Cl = -0.87 to 3.06, I2 = 0%, P = 0.0004). However, it did not have good efficacy on attention. Furthermore, tACS was a very safe treatment. Conclusions tACS is very effective in the treatment of older adults with cognitive impairment, especially for memory function and overall cognition. In addition, tACS is a very safe treatment. However, in the future, there is still a need for many high-quality clinical studies on tACS for cognitive impairment.
- 9 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 128
Efficacy and safety of tACS in older adults with cognitive impairment: a systematic review and meta-analysis
Purpose To assess the safety and effectiveness of tACS as a therapeutic intervention for older adults with cognitive impairment. Materials and methods From the time of library construction until March 3, 2025, we conducted a comprehensive search of the databases PubMed, Embase, Web of Science and Cochrane Library. Additionally, we manually examined the references in the articles. The outcome indicators were cognitive function, which included memory function, attention, overall cognition, as well as safety. Results 6 publications with a total of 888 subjects were included. The tACS group did better at treating cognitive impairment, especially memory problems (SMD = 0.7, 95% Cl = 0.29 to 1.12, I2 = 52%, P = 0.0009) and overall cognition (SMD = 1.97, 95% Cl = -0.87 to 3.06, I2 = 0%, P = 0.0004). However, it did not have good efficacy on attention. Furthermore, tACS was a very safe treatment. Conclusions tACS is very effective in the treatment of older adults with cognitive impairment, especially for memory function and overall cognition. In addition, tACS is a very safe treatment. However, in the future, there is still a need for many high-quality clinical studies on tACS for cognitive impairment.
- Open Access
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , e6521682
Comparison of Clinical Efficiency and Safety Between Intra‐Articular Injection of Platelet‐Rich Plasma and Hyaluronic Acid for Hip Osteoarthritis: A Systematic Review and Meta‐Analysis
Purpose: The aim of this study is to compare the clinical efficacy and safety of platelet‐rich plasma (PRP) and hyaluronic acid in the treatment of hip osteoarthritis. Methods: Data were collected from the PubMed, Embase, Cochrane Library, and Web of Science databases. The outcomes selected included the Visual Analog Scale (VAS) score, the Harris Hip Score (HHS), the Western Ontario, and McMaster Universities Osteoarthritis Index (WOMAC) and its relevant subscores. A standardized mean difference (SMD) was used as the combined effect size, and a random‐effects model was applied for analysis. The magnitude of the effect size was interpreted according to Jacob Cohen’s criteria. Results: A total of seven studies involving 465 patients were included. The meta‐analysis results indicated that in terms of pain relief, the PRP group showed a statistically significant advantage in VAS scores at 6 months (SMD = −0.38 and p = 0.01). Subgroup analysis revealed that LP‐PRP yielded significant improvement (SMD = −0.32 and p = 0.02), whereas LR‐PRP did not (SMD = −0.46 and p = 0.18). Similarly, multiple injections (SMD = −0.43 and p = 0.02) demonstrated superiority compared to a single injection (SMD = −0.12 and p = 0.63).Regarding WOMAC‐pain scores, the PRP group exhibited statistical differences at 6 months (SMD = −0.45 and p = 0.0006) and 12 months (SMD = −0.36 and p = 0.03). In terms of functional impairment, no significant differences were found in the HHS (SMD = 0.13 and p = 0.64) or WOMAC subscores (WOMAC‐stiffness: SMD = 0.01 and p = 0.97 and WOMAC‐function: SMD = −0.24 and p = 0.06) at any follow‐up time point. However, the WOMAC total score indicated that the overall health status of patients in the PRP group was superior to that in the HA group after treatment (SMD = −0.42 and p = 0.009). Discussion: The findings of this study indicate that compared with HA, PRP demonstrates a statistically significant advantage in alleviating pain (VAS and WOMAC‐pain) and improving overall symptoms (WOMAC total score) in patients with hip osteoarthritis (HOA) although the effect size was found to be moderate. However, regarding the improvement of joint function (HHS and WOMAC‐function), no significant differences were observed between the two groups. In summary, while PRP presents a statistical benefit over HA in the treatment of HOA, the effect size is limited; therefore, further high‐quality studies are warranted to definitively confirm its clinical superiority.
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , e6521682
Open AccessComparison of Clinical Efficiency and Safety Between Intra‐Articular Injection of Platelet‐Rich Plasma and Hyaluronic Acid for Hip Osteoarthritis: A Systematic Review and Meta‐Analysis
Purpose: The aim of this study is to compare the clinical efficacy and safety of platelet‐rich plasma (PRP) and hyaluronic acid in the treatment of hip osteoarthritis. Methods: Data were collected from the PubMed, Embase, Cochrane Library, and Web of Science databases. The outcomes selected included the Visual Analog Scale (VAS) score, the Harris Hip Score (HHS), the Western Ontario, and McMaster Universities Osteoarthritis Index (WOMAC) and its relevant subscores. A standardized mean difference (SMD) was used as the combined effect size, and a random‐effects model was applied for analysis. The magnitude of the effect size was interpreted according to Jacob Cohen’s criteria. Results: A total of seven studies involving 465 patients were included. The meta‐analysis results indicated that in terms of pain relief, the PRP group showed a statistically significant advantage in VAS scores at 6 months (SMD = −0.38 and p = 0.01). Subgroup analysis revealed that LP‐PRP yielded significant improvement (SMD = −0.32 and p = 0.02), whereas LR‐PRP did not (SMD = −0.46 and p = 0.18). Similarly, multiple injections (SMD = −0.43 and p = 0.02) demonstrated superiority compared to a single injection (SMD = −0.12 and p = 0.63).Regarding WOMAC‐pain scores, the PRP group exhibited statistical differences at 6 months (SMD = −0.45 and p = 0.0006) and 12 months (SMD = −0.36 and p = 0.03). In terms of functional impairment, no significant differences were found in the HHS (SMD = 0.13 and p = 0.64) or WOMAC subscores (WOMAC‐stiffness: SMD = 0.01 and p = 0.97 and WOMAC‐function: SMD = −0.24 and p = 0.06) at any follow‐up time point. However, the WOMAC total score indicated that the overall health status of patients in the PRP group was superior to that in the HA group after treatment (SMD = −0.42 and p = 0.009). Discussion: The findings of this study indicate that compared with HA, PRP demonstrates a statistically significant advantage in alleviating pain (VAS and WOMAC‐pain) and improving overall symptoms (WOMAC total score) in patients with hip osteoarthritis (HOA) although the effect size was found to be moderate. However, regarding the improvement of joint function (HHS and WOMAC‐function), no significant differences were observed between the two groups. In summary, while PRP presents a statistical benefit over HA in the treatment of HOA, the effect size is limited; therefore, further high‐quality studies are warranted to definitively confirm its clinical superiority.
- Open Access
- 30 June 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1583566
Effects of multi-site non-invasive brain stimulation on cognitive impairment after stroke: a systematic review and meta-analysis
Objective: Post-stroke cognitive impairment (PSCI) is one of the core symptoms following a stroke, which severely affects the prognosis of patients. This systematic review and meta-analysis aim to explore the effectiveness and safety of multi-site non-invasive brain stimulation (MS-NIBS) in enhancing the cognitive function of PSCI patients.Methods: A comprehensive search was conducted in multiple databases, including MEDLINE (PubMed), Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database for Chinese Technical Periodicals, and Chinese Biomedical Literature Database (CBM). The search was performed up to 18 January 2025. The inclusion criteria for this meta-analysis were randomized controlled trials (RCTs) of MS-NIBS for PSCI. The primary outcome measure was the change in the global cognitive scale, while the secondary outcomes focused on improvements in attention, memory, visuospatial perception, and activities of daily living. The Cochrane Risk of Bias Tool was used to assess the quality of each eligible study. Meta-analysis and bias analysis were performed using RevMan (Version 5.3).Results: A total of 6 RCTs involving 416 samples were included in this paper. The findings from the primary outcomes revealed that the MS-NIBS group had significantly higher scores on the Montreal Cognitive Assessment (MOCA) of the cognitive composite scale (MD = 1.84, 95% CI = 1.21–2.48, p < 0.00001, I2 = 36%) compared to the single-site non-invasive brain stimulation (SS-NIBS) group. As for the secondary outcome measures, as shown by the Digit Span Test (DST) forward recall (MD = 0.94, 95% CI = −1.11 to 2.98, p = 0.37, I2 = 97%), DST backward recall (MD = 0.03, 95% CI = −0.24 to 0.29, p = 0.85, I2 = 0%), Clock Drawing Test (CDT) (MD = 1.65, 95% CI = 0.77–2.53, p = 0.0003, I2 = 54%), Trail Making Test (TMT) (MD = 4.2, 95% CI = 2.71–5.69, p < 0.00001, I2 = 14%), and Modified Barthel Index (MBI) for activities of daily living assessment (MD = 3.71, 95% CI = −4.77 to 12.20, p = 0.39, I2 = 75%), the MS-NIBS group showed improvements in visuospatial and trail-making test abilities. Subgroup analysis of the main outcome demonstrated that multi-site transcranial magnetic stimulation (MS-TMS) (MD = 2.1, 95% CI = 1.38–2.81, p < 0.00001, I2 = 48%) and the combined treatment of TMS and transcranial direct current stimulation (tDCS) (MD = 1.91, 95% CI = 0.81–3.01, p = 0.0007, I2 = 0%) exhibited superior efficacy compared to SS-NIBS.Conclusion: This meta-analysis provides evidence supporting that MS-NIBS, as an emerging neuromodulatory tool, is superior to SS-NIBS in improving the overall cognitive abilities of stroke patients. However, given the limited number of included studies, it is necessary to further validate these findings through large-scale, multi-center, double-blind, and high-quality RCTs.Systematic review registration: https://www.crd.york.ac.uk/prospero/, CRD42025640015.
- 30 June 2025
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 19, 1583566
Open AccessEffects of multi-site non-invasive brain stimulation on cognitive impairment after stroke: a systematic review and meta-analysis
Objective: Post-stroke cognitive impairment (PSCI) is one of the core symptoms following a stroke, which severely affects the prognosis of patients. This systematic review and meta-analysis aim to explore the effectiveness and safety of multi-site non-invasive brain stimulation (MS-NIBS) in enhancing the cognitive function of PSCI patients.Methods: A comprehensive search was conducted in multiple databases, including MEDLINE (PubMed), Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database for Chinese Technical Periodicals, and Chinese Biomedical Literature Database (CBM). The search was performed up to 18 January 2025. The inclusion criteria for this meta-analysis were randomized controlled trials (RCTs) of MS-NIBS for PSCI. The primary outcome measure was the change in the global cognitive scale, while the secondary outcomes focused on improvements in attention, memory, visuospatial perception, and activities of daily living. The Cochrane Risk of Bias Tool was used to assess the quality of each eligible study. Meta-analysis and bias analysis were performed using RevMan (Version 5.3).Results: A total of 6 RCTs involving 416 samples were included in this paper. The findings from the primary outcomes revealed that the MS-NIBS group had significantly higher scores on the Montreal Cognitive Assessment (MOCA) of the cognitive composite scale (MD = 1.84, 95% CI = 1.21–2.48, p < 0.00001, I2 = 36%) compared to the single-site non-invasive brain stimulation (SS-NIBS) group. As for the secondary outcome measures, as shown by the Digit Span Test (DST) forward recall (MD = 0.94, 95% CI = −1.11 to 2.98, p = 0.37, I2 = 97%), DST backward recall (MD = 0.03, 95% CI = −0.24 to 0.29, p = 0.85, I2 = 0%), Clock Drawing Test (CDT) (MD = 1.65, 95% CI = 0.77–2.53, p = 0.0003, I2 = 54%), Trail Making Test (TMT) (MD = 4.2, 95% CI = 2.71–5.69, p < 0.00001, I2 = 14%), and Modified Barthel Index (MBI) for activities of daily living assessment (MD = 3.71, 95% CI = −4.77 to 12.20, p = 0.39, I2 = 75%), the MS-NIBS group showed improvements in visuospatial and trail-making test abilities. Subgroup analysis of the main outcome demonstrated that multi-site transcranial magnetic stimulation (MS-TMS) (MD = 2.1, 95% CI = 1.38–2.81, p < 0.00001, I2 = 48%) and the combined treatment of TMS and transcranial direct current stimulation (tDCS) (MD = 1.91, 95% CI = 0.81–3.01, p = 0.0007, I2 = 0%) exhibited superior efficacy compared to SS-NIBS.Conclusion: This meta-analysis provides evidence supporting that MS-NIBS, as an emerging neuromodulatory tool, is superior to SS-NIBS in improving the overall cognitive abilities of stroke patients. However, given the limited number of included studies, it is necessary to further validate these findings through large-scale, multi-center, double-blind, and high-quality RCTs.Systematic review registration: https://www.crd.york.ac.uk/prospero/, CRD42025640015.